

## STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (zz-84)

RALIMETINIB MESYLATE

PRONUNCIATION

ral' i me' ti nib


THERAPEUTIC CLAIM

Antineoplastic

## CHEMICAL NAMES

1. 3*H*-Imidazo[4,5-*b*]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1*H*-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:2)
2. 5-(2-(*tert*-butyl)-4-(4-fluorophenyl)-1*H*-imidazol-5-yl)-3-(2,2-dimethylpropyl)-3*H*-imidazo[4,5-*b*]pyridin-2-amine dimethanesulfonate
3. 5-[2-*tert*-butyl-5-(4-fluoro-phenyl)-1*H*-imidazol-4-yl]-3-(2,2-dimethyl-propyl)-3*H*-imidazo[4,5-*b*]pyridin-2-ylamine dimethanesulfonate

## STRUCTURAL FORMULA



MOLECULAR FORMULA

 $C_{24}H_{29}FN_6 \cdot 2CH_4SO_3$ 

MOLECULAR WEIGHT

612.7

TRADEMARK

None as yet

SPONSOR

Eli Lilly and Company

CODE DESIGNATIONS

LSN2322600, LY2228820 dimesylate

CAS REGISTRY NUMBER

862507-23-1

gbk